Sep 26 |
2 Growth Stocks to Buy With Less Than $100
|
Sep 24 |
Exelixis, Inc.'s (NASDAQ:EXEL) institutional investors lost 4.0% over the past week but have profited from longer-term gains
|
Sep 20 |
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
|
Sep 19 |
Exelixis Faces 'Modest Growth' Prospects, Patent Risk With Limited Near-Term Upside, UBS Says
|
Sep 18 |
A Closer Look at 5 Analyst Recommendations For Exelixis
|
Sep 16 |
Exelixis unveils additional data on Cabometyx for neuroendocrine tumors
|
Sep 16 |
Here's Why Exelixis (EXEL) is a Strong Value Stock
|
Sep 16 |
Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss
|
Sep 16 |
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
|
Sep 15 |
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
|